Longeveron reports Q3 EPS (34c), consensus (44c)

Reports Q3 revenue $210, consensus $400k .”In the third quarter, we continued to advance the development of our investigational cellular therapy candidate, Lomecel-B , as a potential treatment for both Hypoplastic Left Heart Syndrome and mild Alzheimer’s disease,” said Wa’el Hashad, Chief Executive Officer of Longeveron (LGVN). “The ELPIS II clinical trial in HLHS is a key priority and we are delighted to have achieved more than 80% enrollment. Our recent positive Type C meeting with the FDA confirmed ELPIS II is pivotal and, if positive, acceptable for Biological License Application submission for full traditional approval. Similarly, we are excited by the strength of the CLEAR MIND Phase 2a clinical data in mild Alzheimer’s disease and the interest it is garnering with the data selected as a featured research oral presentation at the 2024 Alzheimer’s Association International Conference in July, and additional data selected for Late Breaking poster presentation at the Clinical Trials on Alzheimer’s Disease Conference . We believe stem cell therapy has the potential to become a mainstream treatment for many conditions with significant unmet medical needs and that Longeveron is well positioned to be a leader in stem cell research and potential commercialization.”